Trial opens testing PSMA bispecific antibody plus cancer vaccine in biochemically recurrent prostate cancer
Trial opening · ClinicalTrials.gov · 2026-10-06. Number 5 in the UrologyWatch Top 5 for October 8, 2026.
A phase 2 randomized trial will test a PSMAxCD3 bispecific antibody and a prostate cancer peptide vaccine, alone or combined, in patients with biochemical recurrence after local curative therapy.
Why it matters: Represents an emerging immunotherapy approach being explored in the biochemical recurrence setting.
Source: ClinicalTrials.gov
Loading today's edition…